Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Barbara Herkert,Audrey Kauffmann, Sandra Mollé,Christian Schnell, Thomas Ferrat,Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux,Eric Billy,David Ruddy,Mark Stump,Daniel Guthy, Mitko Ristov,Keith Calkins,Sauveur-Michel Maira,William R. Sellers,Francesco Hofmann,Michael N. Hall,Saskia M. Brachmann

crossref（2023）

引用 0|浏览1

暂无评分

摘要

Concomitant inhibition of PI3Kβ, IGF1R and MAPK signaling are leading to full long-term pathway blockade. A) +B) Effects of treatment with the indicated inhibitors as single-agents or in combination on WM-266-4 (A) or RVH-421 (B) were evaluated by immunoblotting using phospho-specific or total target protein antibodies. PI3Kβi=rac-KIN-193, PI3Kαi=BYL719, IGF1Ri (A)=AEW541, IGF1Ri (B)=Figitumumab-like antibody, MEKi=MEK162

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in &lt;i&gt;PTEN&lt;/i&gt;&lt;sup&gt;LOF&lt;/sup&gt;&lt;i&gt;/BRAF&lt;/i&gt;&lt;sup&gt;MUT&lt;/sup&gt; Melanoma through PI3K and IGF1R Inhibition

Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition